Shadowplay - While I understand your sarcasm and respect your opinions, from a fundamentals perspective, Scrips did have a March Madness with its first month of specialty pharmacy revenues. You're a very bright and savvy investor and, so, I know you see the potential here. I respectfully disagree with your comment about the interview. At this stage in the company's development, Bob is not yet prepared to move the company to the national and more respectable investor presentation circuit (though this circuit does not seem to be doing well for that other company).

Like you, most of the SCRC investors here are in the red and feel quite exhausted after living through the pain of about more than a half a year of heavy dilution and aggressive selling of shares by the toxic noteholders. But most of us can see the tide has turned. I am confident the company will continue to improve and the sp will eventually follow. One of the issues is that SCRC has been beaten down so badly for so long, it appears more is needed to convince the market the company is the real deal and is clearly on the path to profitability. Indeed, as Guts has pointed out, the sp is already over 30% higher than it was 30 days ago. Time is on our side.

Take care,

Bsav